Gilead Reports Loss, but Revenue Rose: COST OF ACQUISITIONS OUTWEIGHED HIGHER DRUG SALES
614065
By Steve Johnson, San Jose Mercury News, Calif.  Jan. 31--Financially burdened by its purchase in November of two companies, Gilead Sciences of Foster City today reported a net loss of $1.67 billion dollars for the fourth quarter of last year.
451417
Gilead announces its fourth-quarter financial results.
29498
Despite its fourth-quarter loss, the pharmaceutical giantâs results topped Wall Street estimates, and its shares rose more than 5 percent.
300389
Amgen  reported on Thursday that its fourth-quarter profit edged higher as cost cutting helped offset declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.
684039
BASEL, Switzerland  - Net profits at Novartis AG  rose by a lower-than-expected 15 percent last year as  restructuring costs weighed, the company reported on Thursday,  but the world's sixth biggest drugmaker said it expects record  sales and profits in 2005.
765525
Gilead Sciences Inc. GILD.O on  Thursday said its quarterly net profit rose 55 percent on  increased sales of its HIV drugs.
549383
THE REGION Genzyme Corp. , maker of enzyme therapies for rare diseases, had a loss in the fourth quarter on acquisition costs but expects higher sales in 2007. The net loss was $268.2 million, or $1.02 a share, versus net income of $106.6 million, or 39 cents, a year earlier, the Cambridge company said. Profit excluding some costs beat analyst ...
289662
Biogen Idec Inc. BIIB.O on Monday  reported a quarterly profit on sales of its multiple sclerosis  and cancer drugs versus a year-ago loss, but said costs will  rise in 2005, trimming earnings growth and weighing on shares.
298049
The pharmaceutical company reported a 5 percent increase in fourth-quarter earnings but said growth would slow this year as generic competition picked up.
336171
YESTERDAY Close $75.73 Change +$2.22 52-WEEK High $76.90 Low $58.71 Genzyme Corp. of Cambridge said profit jumped tenfold as sales increased for its medicines for rare genetic disorders, some of the world's costliest drugs. The company gained 3 percent in New York trading.
501888
Bristol-Myers Squibb Co., a major drug maker, third-quarter profits fell 16 percent as the company struggles with the loss of patent protection on key products but also increases spending on research and development.
746919
Drug maker Schering-Plough Corp   on Tuesday reported a fourth-quarter loss as special  charges from its acquisition of Organon Biosciences late last  year offset sharply higher sales.
20746
Sales are strong, but the bookseller still sees a significant loss in Q2.
70317
MedImmune Inc. reported a third-quarter loss yesterday, despite $61 million in sales of its lead product, Synagis, a 25 percent increase over the same period a year ago.
730824
Charges hurt the quarterly results of Johnson & Johnson, Merck & Co. and Schering-Plough Corp., but the drugmakers' shares rose as J&J's earnings beat Wall Street forecasts and Merck sales edged higher despite the withdrawal of its best-selling Vioxx arthritis drug.
515541
INDIANAPOLIS, July 24  â Eli Lilly, with help from its core medicines Zyprexa and Cymbalta, beat Wall Streetâs second-quarter expectations Tuesday, although profits fell 19 percent at the pharmaceutical company because of acquisition costs.
272055
MedImmune Inc. reported a third-quarter loss Thursday, despite a $61 million, 25 percent increase in sales of its lead product, Synagis, over the same period a year ago.